Posting of Circular and Notice of General Meeting

24 July 2024

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Posting of Circular and Notice of General Meeting

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces further to the announcement made earlier today relating to its proposed Firm Placing, Conditional Placing and Subscription to raise approximately £2.83 million ("Announcement"), that it has despatched the Circular and Notice of General Meeting to Shareholders.

The Directors confirm they are to convene a General Meeting of the Company at 11:00 a.m. on Tuesday 13 August 2024 at Windmill House, Innovation Way, York, YO10 5BR.

The Circular and Notice of General Meeting is available on the Company's website at https://aptamergroup.com/investors/reports-and-presentations/

The results of voting on all resolutions at the General Meeting will be announced via a Regulatory News Service and the full results of the voting will be published on the Company's website, as soon as practicable after the conclusion of the General Meeting.

Capitalised terms used but not otherwise defined in this announcement shall have the meanings ascribed to such terms in the Announcement, unless the context requires otherwise.

- ENDS -

For further information, please contact:

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer® platform.

Optimer® binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion. Optimer® binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies, diagnostic development companies and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer® technology and processes, scientists and collaborators can make faster, more informed decisions that support discovery and development across the Life Sciences.